ALT持续正常的慢乙肝患者组织学特点及相关影响因素研究进展
Research Progress in Histological Features and Related Influencing Factors of Chronic Hepatitis B Patients with Persistent Normal ALT
摘要: 慢性乙型肝炎(Chronic Hepatitis B, CHB)是由乙型肝炎病毒(HBV)引起的一种慢性肝炎,是引起肝癌的主要病因。临床上评估肝脏炎症的常见无创指标为丙氨酸氨基转移酶(ALT),一般认为,ALT水平正常的乙肝病毒(HBV)感染患者,要么处于乙肝自然史的免疫耐受阶段,要么处于低复制阶段,肝组织没有或只有轻度炎症,不建议进行抗病毒治疗。然而,ALT水平正常的慢性HBV感染患者并不总是处于稳定状态,最近有大量研究表明,ALT保持正常的CHB患者存在不同程度的中度和重度炎症或明显的纤维化,甚至肝硬化,对于此类患者,是否抗病毒治疗以及何时开始抗病毒治疗仍是临床实践中的热点问题,本文就ALT持续正常的CHB患者的肝组织学特点及其相关影响因素进行综述,旨在改善临床对于此类患者抗病毒治疗指征。
Abstract: Chronic Hepatitis B (CHB) is a chronic hepatitis caused by the hepatitis B virus (HBV) and is the leading cause of liver cancer. Alanine aminotransferase (ALT) is a common noninvasive marker for clinical evaluation of liver inflammation. It is generally believed that patients infected with hepati-tis B virus (HBV) with normal ALT level are either at the immune tolerance stage of the natural his-tory of hepatitis B or at the low replication stage, with no or only mild inflammation of the liver tis-sue, and antiviral therapy is not recommended. However, patients with chronic HBV infection with normal ALT levels are not always in a stable state. A large number of recent studies have shown that patients with CHB who maintain normal ALT have varying degrees of moderate and severe inflam-mation or significant fibrosis or even cirrhosis. For such patients, is antiviral therapy available? When to start antiviral therapy? It is still a hot topic in clinical practice. This paper reviews the liver histological features and related influencing factors of CHB patients with persistent normal ALT, aiming to improve clinical indications for antiviral therapy in such patients.
文章引用:刘宇行, 胡鹏. ALT持续正常的慢乙肝患者组织学特点及相关影响因素研究进展[J]. 临床医学进展, 2023, 13(5): 8702-8707. https://doi.org/10.12677/ACM.2023.1351216

参考文献

[1] The Korean Association for the Study of the Liver (KASL) (2022) KASL Clinical Practice Guidelines for Management of Chronic Hepatitis B. Clinical and Molecular Hepatology, 28, 276-331. [Google Scholar] [CrossRef] [PubMed]
[2] Boora, S., Sharma, V., Kaushik, S., Bhupatiraju, A., Singh, S. and Kaushik, S. (2023) Hepatitis B Virus-Induced Hepatocellular Carcinoma: A Persistent Global Problem. Brazilian Journal of Microbiology. [Google Scholar] [CrossRef] [PubMed]
[3] (2021) Global Progress Report on HIV, Viral Hepatitis and Sexually Transmitted Infections. Accountability for the Global Health Sector Strategies 2016-2021: Actions for Impact.
https://apps.who.int/iris/bitstream/handle/10665/342808/9789240030985-eng.pdf
[4] Cui, F., Blach, S., Man-zengo Mingiedi, C., et al. (2023) Global Reporting of Progress towards Elimination of Hepatitis B and Hepatitis C. The Lancet Gastroenterology & Hepatology, 8, 332-342. [Google Scholar] [CrossRef
[5] Nguyen, M.H., Wong, G., Gane, E., Kao, J.H. and Dusheiko, G. (2020) Hepatitis B Virus: Advances in Prevention, Diagnosis, and Therapy. Clinical Microbiology Reviews, 33, e00046-19. [Google Scholar] [CrossRef
[6] 王贵强, 王福生, 成军, 等. 慢性乙型肝炎防治指南(2015年版) [J]. 中华实验和临床感染病杂志, 2015, 19(5): 1-18.
[7] Terrault, N.A., Lok, A.S.F., McMahon, B.J., Chang, K.M., Hwang, J.P., Jonas, M.M., et al. (2018) Update on Prevention, Diagnosis, and Treatment of Chronic Hep-atitis B: AASLD 2018 Hepatitis B Guidance. Hepatology, 67, 1560-1599. [Google Scholar] [CrossRef] [PubMed]
[8] Xu, Y., Liu, H., Wang, Y., Hao, R., Li, Z. and Song, H. (2013) The Next Step in Controlling HBV in China. BMJ, 347, f4503-f4503. [Google Scholar] [CrossRef] [PubMed]
[9] (2017) EASL 2017 Clinical Practice Guidelines on the Management of Hepatitis B Virus Infection. Journal of Hepatology, 67, 370-398. [Google Scholar] [CrossRef] [PubMed]
[10] 中华医学会肝病学分会, 中华医学会感染病学分会. 慢性乙型肝炎防治指南(2022年版) [J]. 中华肝脏病杂志, 2022, 30(12): 1309-1331. [Google Scholar] [CrossRef] [PubMed]
[11] 宁会彬, 尚佳. 年龄不应作为ALT正常的慢性HBV感染患者抗病毒治疗的束缚[J]. 中华肝脏病杂志, 2022, 30(11): 1246-1247. [Google Scholar] [CrossRef] [PubMed]
[12] Lin, C., Liao, L., Liu, C., et al. (2007) Hepatitis B Viral Factors in HBeAg-Negative Carriers with Persistently Normal Serum Alanine Aminotransferase Levels. Hepatolo-gy (Baltimore, Md), 45, 1193-1198. [Google Scholar] [CrossRef] [PubMed]
[13] 宁会彬, 靳慧鸣, 李宽, 彭真, 尚佳. 丙氨酸转氨酶正常的乙型肝炎e抗原阴性慢性乙型肝炎患者的肝脏病理特征及血清学无创诊断模型价值分析[J]. 中华传染病杂志, 2022, 40(12): 729-734. [Google Scholar] [CrossRef
[14] 刘勇, 邹亚文, 孙嬴, 王雪梅, 余祖江. 谷丙转氨酶持续正常HBeAg阳性慢性HBV感染者肝组织学病变的独立危险因素探讨及无创模型建立[J]. 河南医学研究, 2022(3): 31.
[15] Sarin, S.K., Kumar, M., Lau, G.K., Abbas, Z., Chan, H.L., Chen, C.J., et al. (2016) Asian-Pacific Clinical Practice Guidelines on the Management of Hepatitis B: A 2015 Update. Hepatology International, 10, 1-98. [Google Scholar] [CrossRef] [PubMed]
[16] Liao, B., Wang, Z., Lin, S., Xu, Y., Yi, J., Xu, M., Huang, Z., Zhou, Y., Zhang, F. and Hou, J. (2013) Significant Fibrosis Is Not Rare in Chinese Chronic Hepatitis B Patients with Persistent Normal ALT. PLOS ONE, 8, e78672. [Google Scholar] [CrossRef] [PubMed]
[17] Tan, Y.W., Zhou, X.B., Ye, Y., He, C. and Ge, G.H. (2017) Diagnostic Value of FIB-4, Aspartate Aminotransferase-to-Platelet Ratio Index and Liver Stiffness Measurement in Hep-atitis B Virus-Infected Patients with Persistently Normal Alanine Aminotransferase. World Journal of Gastroenterology, 23, 5746-5754. [Google Scholar] [CrossRef] [PubMed]
[18] Tan, Y., Ye, Y., Zhou, X., Chen, L. and Wen, D. (2015) Age as a Predictor of Significant Fibrosis Features in HBeAg-Negative Chronic Hepatitis B Virus Infection with Persistently Normal Alanine Aminotransferase. PLOS ONE, 10, e0123452. [Google Scholar] [CrossRef] [PubMed]
[19] Papatheodoridis, G.V., Manesis, E.K., Manolakopoulos, S., Elefsiniotis, I.S., Goulis, J., Giannousis, J., et al. (2008) Is There a Meaningful Serum Hepatitis B Virus DNA Cutoff Level for Therapeutic Decisions in Hepatitis B e Antigen-Negative Chronic Hepatitis B Virus Infection? Hepatology, 48, 1451-1459. [Google Scholar] [CrossRef] [PubMed]
[20] Zhang, C., Li, J.W., Wu, Z., Zhao, H. and Wang, G.Q. (2021) Significant Histologic Changes Are Not Rare in Treatment-Naive Hepatitis B Patients with Normal Alanine Aminotrans-ferase Level: A Meta-Analysis. Journal of Clinical and Translational Hepatology, 9, 615-625. [Google Scholar] [CrossRef
[21] Yoo, J.-J., et al. (2023) Long-Term Prognosis and the Need for Histologic Assessment of Chronic Hepatitis B in the Serological Immune-Tolerant Phase. Clinical and Molecular Hepa-tology, 29, 482-495. [Google Scholar] [CrossRef] [PubMed]
[22] Feng, M., Lei, L., Xu, J., Shi, Y. and Yang, W. (2022) Plate-let-to-Portal Vein Width Ratio and Platelet-to-Spleen Thickness Ratio Can Be Used to Predict Progressive Liver Fibrosis among Patients with HBV Infection with HBeAg- Negativity and a Normal ALT Level. Frontiers in Medicine, 9, Article ID: 837898. [Google Scholar] [CrossRef] [PubMed]
[23] Duan, M., Chi, X., Xiao, H., et al. (2021) High-Normal Alanine Aminotransferase Is an Indicator for Liver Histopathology in HBeAg Negative Chronic Hepatitis B. Hepatology Interna-tional, 15, 318-327. [Google Scholar] [CrossRef] [PubMed]
[24] Wang, H., Ru, G.Q., Yan, R., Zhou, Y., Wang, M.S. and Cheng, M.J. (2016) Histologic Disease in Chinese Chronic Hepatitis B Patients with Low Viral Loads and Persistently Normal Alanine Aminotransferase Levels. Journal of Clinical Gastroenterology, 50, 790-796. [Google Scholar] [CrossRef
[25] Assy, N., Beniashvili, Z., Djibre, A., Nasser, G., Gro-sovski, M. and Nseir, W. (2009) Lower Baseline ALT Cut-Off Values and HBV DNA Levels Better Differentiate HBeAg-Chronic Hepatitis B Patients from Inactive Chronic Carriers. World Journal of Gastroenterology, 15, 3025-3031. [Google Scholar] [CrossRef] [PubMed]
[26] Gui, H.L., Wang, H., Yang, Y.H., Wu, Y.W., Zhou, H.J., Guo, S.M., Lin, L.Y., Wang, L., Cai, W., Chen, R., Guo, Q., Zhou, X.Q., Bao, S.S. and Xie, Q. (2010) Significant Histopathology in Chinese Chronic Hepatitis B Patients with Persistently High-Normal Alanine Aminotransferase. Journal of Viral Hep-atitis, 17, 44-50. [Google Scholar] [CrossRef] [PubMed]
[27] 周璇, 李维正, 马文婷, 薛冬英. ALT正常慢性HBV感染者肝组织病理与年龄, ALT和HBV DNA水平相关性研究[J]. 肝脏, 2019, 24(10): 1141-1144.
[28] Zoulim, F. and Mason, W.S. (2012) Reasons to Consider Earlier Treatment of Chronic HBV Infections. Gut, 61, 333-336. [Google Scholar] [CrossRef] [PubMed]
[29] Huang, D., Li, X., Le, M.H., Le, A.K., Yeo, Y.H., Trinh, H.N., et al. (2022) Natural History and Hepatocellular Carcinoma Risk in Untreated Chronic Hepatitis b Patients with Indetermi-nate Phase. Clinical Gastroenterology and Hepatology, 20, 1803-1812.e5. [Google Scholar] [CrossRef] [PubMed]
[30] Ren, S., Wang, W., Lu, J., Wang, K., Ma, L., Zheng, Y., Zheng, S. and Chen, X. (2022) Effect of the Change in Antiviral Therapy Indication on Identifying Significant Liver Injury among Chronic Hepatitis B Virus Infections in the Grey Zone. Frontiers in Immunology, 13, Article ID: 1035923. [Google Scholar] [CrossRef] [PubMed]
[31] 中华医学会肝病学分会. 扩大慢性乙型肝炎抗病毒治疗的专家意见[J]. 中华肝脏病杂志, 2022, 30(2): 131-136. [Google Scholar] [CrossRef] [PubMed]